Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Previously Treated Multiple Myeloma
NCT01242930Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Nov 2010
- Primary completion
- Nov 2014
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imetelstat in multiple myeloma (MM) (2 arms), sponsored by Geron Corporation. Primary endpoint: Rate of Improvement in Response at 12 months. Started Nov 2010; status: completed.
02
Drugs
imetelstat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01242930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242930.